{"organizations": [], "uuid": "f1fd202fb3aea161b9cc40a5d9dc69672f54c2ca", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kubota-pharmaceutical-holdings-uni/brief-kubota-pharmaceutical-holdings-unit-and-sirion-biotech-set-sights-on-gene-delivery-tools-for-ocular-gene-therapy-idUSL4N1P41HD", "country": "US", "domain_rank": 408, "title": "BRIEF-Kubota Pharmaceutical Holdings unit and SIRION Biotech set sights on gene delivery tools for ocular gene therapy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-01-09T10:31:00.000+02:00", "replies_count": 0, "uuid": "f1fd202fb3aea161b9cc40a5d9dc69672f54c2ca"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kubota-pharmaceutical-holdings-uni/brief-kubota-pharmaceutical-holdings-unit-and-sirion-biotech-set-sights-on-gene-delivery-tools-for-ocular-gene-therapy-idUSL4N1P41HD", "ord_in_thread": 0, "title": "BRIEF-Kubota Pharmaceutical Holdings unit and SIRION Biotech set sights on gene delivery tools for ocular gene therapy", "locations": [], "entities": {"persons": [], "locations": [{"name": "sirion", "sentiment": "none"}], "organizations": [{"name": "brief-kubota pharmaceutical holdings", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "kubota pharmaceutical holdings co ltd", "sentiment": "negative"}, {"name": "acucela inc", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 9 (Reuters) - Kubota Pharmaceutical Holdings Co Ltd\n* Says coâ€™s wholly owned unit Acucela Inc signed a two-year development agreement with gene delivery expert SIRION Biotech GmbH (SIRION) to establish optimized AAV vectors for clinical applications in ocular gene therapy\n* Says Acucela bolsters its move into the fast growing gene therapy market to find a genetic cure for retinitis pigmentosa\n* Key terms of the agreement include milestone payments to SIRION, with additional royalties to be paid on net sales from resulting products or therapies\nSource text in Japanese: goo.gl/n8VbQu\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/n8VbQu", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-09T10:31:00.000+02:00", "crawled": "2018-01-09T17:05:52.056+02:00", "highlightTitle": ""}